Topotecan (injection)

Topotecan (injection)

Clinical data
Pregnancy category	D (Au, U.S.)
Routes of administration	Intravenous infusion, oral
ATC code	L01XX17 (WHO)
Legal status
Legal status	℞-only (U.S.), POM (UK)
Pharmacokinetic data
Bioavailability	NA
Protein binding	35%
Metabolism	Hepatic
Elimination half-life	2-3 hours
Excretion	Renal
Identifiers
IUPAC name (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9- dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b] quinoline-3,14(4H,12H)-dione monohydrochloride
CAS Number	119413-54-6
PubChem CID	6419854
DrugBank	APRD00687
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C23H23N3O5 •HCl
Molar mass	457.9 g/mol

WikiDoc Resources for Topotecan (injection)
Articles
Most recent articles on Topotecan (injection) Most cited articles on Topotecan (injection) Review articles on Topotecan (injection) Articles on Topotecan (injection) in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Topotecan (injection) Images of Topotecan (injection) Photos of Topotecan (injection) Podcasts & MP3s on Topotecan (injection) Videos on Topotecan (injection)
Evidence Based Medicine
Cochrane Collaboration on Topotecan (injection) Bandolier on Topotecan (injection) TRIP on Topotecan (injection)
Clinical Trials
Ongoing Trials on Topotecan (injection) at Clinical Trials.gov Trial results on Topotecan (injection) Clinical Trials on Topotecan (injection) at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Topotecan (injection) NICE Guidance on Topotecan (injection) NHS PRODIGY Guidance FDA on Topotecan (injection) CDC on Topotecan (injection)
Books
Books on Topotecan (injection)
News
Topotecan (injection) in the news Be alerted to news on Topotecan (injection) News trends on Topotecan (injection)
Commentary
Blogs on Topotecan (injection)
Definitions
Definitions of Topotecan (injection)
Patient Resources / Community
Patient resources on Topotecan (injection) Discussion groups on Topotecan (injection) Patient Handouts on Topotecan (injection) Directions to Hospitals Treating Topotecan (injection) Risk calculators and risk factors for Topotecan (injection)
Healthcare Provider Resources
Symptoms of Topotecan (injection) Causes & Risk Factors for Topotecan (injection) Diagnostic studies for Topotecan (injection) Treatment of Topotecan (injection)
Continuing Medical Education (CME)
CME Programs on Topotecan (injection)
International
Topotecan (injection) en Espanol Topotecan (injection) en Francais
Business
Topotecan (injection) in the Marketplace Patents on Topotecan (injection)
Experimental / Informatics
List of terms related to Topotecan (injection)

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Topotecan hydrochloride (Hycamtin) is a chemotherapy agent that is a topoisomerase 1 inhibitor. It is used to treat ovarian cancer and lung cancer, as well as other cancer types.

After GlaxoSmithKline received final FDA approval for Hycamtin Capsules on October 15, 2007, Topotecan is the first topoisomerase inhibitor for oral use.

Administration

IV, oral.

Side effects

• Diarrhea
• Low blood counts
• Susceptibility to infection

See also

NCI Drug Dictionary Definition of Topotecan
NCI Drug Information for Patients